
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene t... Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated; and LX2022, a gene therapy candidate for the treatment of HCM caused by TNNI3 mutations. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York. Show more
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.3 | -10 | 3 | 3.3838 | 2.32 | 961751 | 2.58692261 | CS |
4 | -2.63 | -49.3433395872 | 5.33 | 5.54 | 2.32 | 531256 | 3.31779324 | CS |
12 | -4.31 | -61.4835948645 | 7.01 | 7.66 | 2.32 | 313554 | 4.42886188 | CS |
26 | -8.1 | -75 | 10.8 | 11.72 | 2.32 | 373410 | 7.02201302 | CS |
52 | -12.17 | -81.8426361802 | 14.87 | 19.5 | 2.32 | 296618 | 9.6673827 | CS |
156 | -6.8 | -71.5789473684 | 9.5 | 22.33 | 2.32 | 250252 | 10.10676767 | CS |
260 | -6.8 | -71.5789473684 | 9.5 | 22.33 | 2.32 | 250252 | 10.10676767 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions